Patents Represented by Attorney, Agent or Law Firm Janet E. Hasak
  • Plasma carboxypeptidase
    Patent number: 5364934
    Abstract: A novel polypeptide, designated plasma carboxypeptidase B (PCPB), has been purified from human plasma. It has been cloned from a human liver cDNA library using PCR amplification. Provided herein is nucleic acid encoding PCPB useful in diagnostics and in the recombinant preparation of PCPB. PCPB is used in the preparation and purification of antibodies thereto, in the purification of plasminogen, in the inhibition of plasminogen activation by t-PA in the presence of fibrinogen, and in diagnostic assays.
    Type: Grant
    Filed: December 15, 1993
    Date of Patent: November 15, 1994
    Assignee: Genentech, Inc.
    Inventors: Dennis T. Drayna, Dan L. Eaton
  • DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
    Patent number: 5346824
    Abstract: A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The variants may be used in a pharmaceutical preparation to treat a vascular disease or condition in patients.
    Type: Grant
    Filed: March 22, 1993
    Date of Patent: September 13, 1994
    Assignee: Genentech, Inc.
    Inventors: Stephen Anderson, Kevin M. Brady, Bruce A. Keyt, Leonard G. Presta
  • Method for producing polypeptide via bacterial fermentation
    Patent number: 5342763
    Abstract: A process for producing a polypeptide of interest from fermentation of bacterial host cells comprising nucleic acid encoding the polypeptide is provided. In this method, the host cells employed have an inactivated electron transport chain. Further provided is a method for determining if a particular bacterial cell culture has a propensity for dissolved oxygen instability when fermented on a large scale.
    Type: Grant
    Filed: November 23, 1992
    Date of Patent: August 30, 1994
    Assignee: Genentech, Inc.
    Inventor: James R. Swartz
  • CD4 adheson variants
    Patent number: 5336603
    Abstract: Novel derivatives of cell surface proteins which are homologous to the immunoglobulin superfamily (adhesons) are provided. Amino acid sequence variations are introduced into adheson, the most noteworthy of which are those in which the transmembrane and, preferably, cytoplasmic domains are rendered functionally inactive, and in which adheson extracellular domains replace an immunoglobulin variable region. These variants are useful in therapy or diagnostics.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: August 9, 1994
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Capon, Timothy J. Gregory
  • Insulin-like growth factor binding protein and pharmaceutical compositions
    Patent number: 5328891
    Abstract: DNA isolates coding for insulin-like growth factor binding protein may be used to produce the protein via recombinant expression systems. Insulin-like growth factor binding protein, which generally has a molecular weight of about 53 kD on non-reducing SDS-PAGE, is useful as a binder to insulin-like growth factor and as a metabolic regulator.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: July 12, 1994
    Assignees: Genentech, Inc., Central Sydney Area Health Service
    Inventors: Robert C. Baxter, William I. Wood
  • Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
    Patent number: 5324820
    Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: June 28, 1994
    Assignee: Central Sydney Area Health Service
    Inventor: Robert C. Baxter
  • Nucleic acid encoding the .alpha. chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
    Patent number: 5310661
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. or .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: October 8, 1992
    Date of Patent: May 10, 1994
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • Method of controlling polypeptide production in bacterial cells
    Patent number: 5304472
    Abstract: Nucleic acid is provided encoding a molecule having certain variations within the phosphate-binding region of native E. coli PstS. Additionally provided are bacterial cells comprising this nucleic acid under control of the native pstS gene promoter, and optionally further comprising nucleic acid encoding a polypeptide of interest under control of the alkaline phosphatase (AP) promoter. Bacterial cells containing both pstS variant nucleic acid and polypeptide nucleic acid are cultured in a medium at a concentration of inorganic phosphate that at all phases of cell growth is above the level at which the cells are starved for phosphate. Alternatively, the cells are cultured under conditions whereby the concentration of inorganic phosphate in the culture medium is controlled during the production period so that the polypeptide is produced under the control of the partially induced AP promoter.
    Type: Grant
    Filed: November 20, 1992
    Date of Patent: April 19, 1994
    Assignee: Genentech, Inc.
    Inventors: Steven Bass, James R. Swartz
  • Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
    Patent number: 5288931
    Abstract: A method for refolding insoluble, improperly folded IGF-I is provided, wherein the IGF-I, precipitated from prokaryotic host cells, it concurrently solubilized, unfolded, and refolded into a biologically active conformation in a single buffer. The buffer contains reducing agent and chaotropic agent to solubilize the IGF-I at concentrations sufficiently low to allow solubilization and folding to occur. Also provided is a triple-protease deficient E. coli host suitable for use in the process.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: February 22, 1994
    Assignee: Genentech, Inc.
    Inventors: Judy Y. Chang, Nancy C. McFarland, James R. Swartz
  • Detection and purification of activin polypeptide
    Patent number: 5286654
    Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: February 15, 1994
    Assignee: Genentech, Inc.
    Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
  • Nucleic acid encoding TGF-.beta. and its uses
    Patent number: 5284763
    Abstract: Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TGF-.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TGF-.beta. is useful in diagnosis and identification of TGF-.beta. clones.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: February 8, 1994
    Assignee: Genentech, Inc.
    Inventors: Rik M. A. Derynk, David V. Goeddel
  • Method of prophylaxis of acute renal failure
    Patent number: 5273961
    Abstract: A method is disclosed for the prophylactic treatment of mammals at risk for acute renal failure, whether due to renal ischemia or nephrotoxic damage. This method involves administering to the mammal, before or at the time that the acute renal failure is expected to occur or is occurring, an effective amount of IGF-I. Preferably, the IGF-I is native-sequence, mature human IGF-I.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: December 28, 1993
    Assignee: Genentech, Inc.
    Inventor: Ross G. Clark
  • Process for making biologically active polypeptides based on transforming growth factor-.beta.sequences
    Patent number: 5268455
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta. molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-As p-Leu, the polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: January 23, 1992
    Date of Patent: December 7, 1993
    Assignee: Genentech, Inc.
    Inventor: George J. Cianciolo
  • Host transformed with yeast gene and ubiquitin/polypeptide fusions
    Patent number: 5262322
    Abstract: A ubiquitin hydrolase is provided having a purity of at least 70% homogeneity based on the weight of the total protein in the composition. Also provided are DNA sequences encoding ubiquitin hydrolases, as well as expression systems for their recombinant production. Processes are provided for purification of a ubiquitin hydrolase from eukaryotes and for its use in recovering any desired polypeptide free from its fusion at its N-terminus with ubiquitin.
    Type: Grant
    Filed: April 30, 1991
    Date of Patent: November 16, 1993
    Assignee: Genentech, Inc.
    Inventors: Chung-Cheng Liu, Harvey I. Miller
  • DNA encoding and methods of production of insulin-like growth factor binding protein BP53
    Patent number: 5258287
    Abstract: DNA isolates coding for insulin-like growth factor binding protein may be used to produce the protein via recombinant expression systems. Insulin-like growth factor binding protein, which generally has a molecular weight of about 53 kD on non-reducing SDS-PAGE, is useful as a binder to insulin-like growth factor and as a metabolic regulator.
    Type: Grant
    Filed: March 22, 1988
    Date of Patent: November 2, 1993
    Assignees: Genentech, Inc., Central Sydney Area Health Service
    Inventors: Robert C. Baxter, William I. Wood
  • Tangential flow filtration process and apparatus
    Patent number: 5256294
    Abstract: Processes and apparati are provided for separating species of interest from a mixture containing them which comprises subjecting the mixture to tangential-flow filtration, wherein the filtration membrane preferably has a pore size that retains species with a size up to about 10 microns, and the flux is maintained at a level ranging from about 5% up to 100% of transition point flux.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: October 26, 1993
    Assignee: Genentech, Inc.
    Inventor: Robert D. van Reis
  • Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
    Patent number: 5215893
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. and .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: June 1, 1993
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • Receptor polypeptides and their production and uses
    Patent number: 5216126
    Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: June 1, 1993
    Assignee: Genentech, Inc.
    Inventors: Edward T. Cox, Jennie P. Mather, Mary B. Sliwkowski, Teresa K. Woodruff
  • Human plasma carboxypeptidase B
    Patent number: 5206161
    Abstract: A novel polypeptide, designated plasma carboxypeptidase B (PCPB), has been purified from human plasma. It has been cloned from a human liver cDNA library using PCR amplification. Provided herein is nucleic acid encoding PCPB useful in diagnostics and in the recombinant preparation of PCPB. PCPB is used in the preparation and purification of antibodies thereto, in the purification of plasminogen, in the inhibition of plasminogen activation by t-PA in the presence of fibrinogen, and in diagnostic assays.
    Type: Grant
    Filed: February 1, 1991
    Date of Patent: April 27, 1993
    Assignee: Genentech, Inc.
    Inventors: Dennis T. Drayna, Dan L. Eaton
  • Interleukin-2 muteins and polymer conjugation thereof
    Patent number: 5206344
    Abstract: Muteins of IL-2 in which one of the amino acids of the mature native sequence of IL-2 is replaced by a cysteine residue are prepared and conjugated through the replaced cysteine residue to a polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols, wherein said homopolymers are unsubstituted or substituted at one end with an alkyl group. These muteins are made via host expression of mutant genes encoding the muteins that have been changed from the genes for the parent proteins by site-directed mutagenesis. In addition, other species of IL-2 may be conjugated via the cysteine residue at position 125 of the mature IL-2 protein that is not necessary for the biological activity of the IL-2.
    Type: Grant
    Filed: January 11, 1988
    Date of Patent: April 27, 1993
    Assignee: Cetus Oncology Corporation
    Inventors: Nandini Katre, Robert F. Halenbeck, Robert J. Goodson, Peter C. McCabe, Michael J. Knauf